Thanks to the whole CHOCO team for their contributions.

Open access link: https://onlinelibrary.wiley.com/doi/10.1002/adsc.202301285?af=R

We are happy to be involved and able to contribute and learn more on how to degrade presistant chemical pollutants in soil and waste water.

The thesis “Exploring the Potential of CO2: Enantioselective C-C Bond Formation” can be found here: https://munin.uit.no/handle/10037/32994.

You can find the paper by following the following link: https://doi.org/10.1016/j.ejmech.2024.116140

For popular science communication on Manuel´s work you can read here:

Forskning.no (in norwegian): https://www.forskning.no/antibiotikaresistens-bakterier-helse/forskere-har-laget-draps-molekyler-som-tar-knekken-pa-bakterier/2205204

AMR insights: https://www.amr-insights.eu/making-antibacterial-supermolecules/

UiT.no: httphttps://en.uit.no/news/article?p_document_id=811730s://en.uit.no/news/article?p_document_id=811730

Sasha gave a talk on the development of b-lactam-inhibitor conjugates.

A very worthy ending of 4-years of thesis work. I am a proud supervisor. And a big thanks to the co-supervisors Klara Stensvåg and Morten B. Strøm and the evaluation committee Nathaniel Martin, Yngve Stenstrøm, and Anna-Louisa Warnke.

We went together with Jhonnathan and Marie (our collueagues in the CHOCO group). Martin presented his research. And Dat presented a poster. Well done!

The Erdelyi group has studied the binding of our inhibitors in VIM-2.

Wieske LHE, Bogaerts J, Leding AAM, Wilcox S, Rasmussen AA, Leszczak K, Turunen L, Herrebout WA, Hubert M, Bayer A, Erdélyi M. ACS Med. Chem. Lett., 2022, 257-61. NMR Backbone Assignment of VIM-2 and Identification of the Active Enantiomer of a Potential Inhibitor. doi: 10.1021/acsmedchemlett.1c00635

Marianne´s and Manuel´s work on antimicrobial barbiturates was accepted to J. Med. Chem. Hurray and thank you to all the fine collaborators who contributed to the work.

Amphipathic Barbiturates as Mimics of Antimicrobial Peptides and the Marine Natural Products Eusynstyelamides with Activity against Multi-resistant Clinical Isolates.